Skip to main content

Table 3 Laboratory parameters of patients treated with levosimendan

From: Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study

A) Acute heart failure (n = 16)

   

Laboratory parameters

before levosimendan

after levosimendan

P value

Leukocytes (G/L)

10.5 (8.3-14.8)

10.5 (7.4-15.7)

ns

CRP (mg/dL)

3.2 (0.6-4.1)

3.1 (1.7-7.4)

ns

Procalcitonin (μg/L)

0.3 (0.1-1.4)

0.4 (0.2-0.8)

ns

Serum IL - 6 (pg/mL)

51 (34-327)

44 (38-136)

ns

Urea (mg/dL)

75 (56-125)

73 (51-150)

ns

Creatinine (mg/dL)

1.6 (0.9-2.4)

1.3 (0.8-2.3)

ns

Serum cystatin C (mg/L)

1.6 (1.3-2.4)

1.7 (1.3-2.6)

ns

B) Septic cardiac failure (n = 9)

   

Laboratory parameters

before levosimendan

after start levosimendan

P value

Leucocytes (G/L)

10.5 (7.6-16.3)

11.6 (8.2-14.5)

ns

CRP (mg/dL)

14.9 (9.0-21.4)

14.2 (5.3-21.5)

ns

Procalcitonin (μg/L)

4.8 (1.1-26.9)

2.8 (1.1-21.3)

ns

Serum IL-6 (pg/mL)

649 (387-1097)

787 (477-1033)

ns

Urea (mg/dL)

76 (47-128)

82 (46-159)

ns

Creatinine (mg/dL)

1.4 (0.8-2.5)

1.6 (0.7-2.1)

ns

Serum cystatin C (mg/L)

2.3 (2.0-3.1)

2.4 (2.0-3.0)

ns

  1. Table shows laboratory parameters of (a) patients with acute heart failure (n = 16) and (b) patients with septic cardiac failure (n = 9) before levosimendan treatment and after levosimendan treatment (after 24 hours); Data are expressed as median (interquartile range). CRP, C-reactive protein; ns, not significant.